Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 26, 2010
app pub date -
Apr 30, 2010
filing date -
May 10, 2004
priority date (Note) -
Abandoned
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Abstract
L) and/or their dry milled fractions such as seed coats or hulls and cotyledons is described. These phytochemicals are classified as phenolics, such as polyphenols, flavonoids, coumarins, and tannins, triterpenes such as saponins, phytosterols and other antioxidant compounds that proved to be effective to decrease cancer proliferation of hormone dependent mammary (MCF-7), hormone independent hepatic (HepG2) and colon (Caco2) cancer cells. They also effectively protect against chemical damage induced with DMBA and furthermore prevented cancer induced by this chemical in Wistar rats and also reduced tumor size when consumed after tumor detection. Methanol, acetone, ethanol, water and mixtures of these solvents were used to obtain the extracts from raw, cooked, and germinated black beans of different varieties, both from the whole grain and the hulls. The black bean malting process produced extracts rich in aglycone forms of the previous mentioned compounds that were more biologically active against MCF-7 cancer cell proliferation. Both raw extracts, C-18 HPLC refined extracts and fractionated extracts may be used in the treatment, prophylaxis, amelioration or defense against a variety of hormone dependent and independent cancers. The extracts and compounds have additional utilities, e.g., lower cholesterol or lower oxidation of LDL and/or inhibit cholesterol synthesis (or the enzyme therefor) and/or reduce liver fibrosis and/or reduce symptoms of menopause and/or stimulate calcium absorption and/or have estrogenic activity such as feminizing estrogenic activity and/or are antioxidants, for instance, as an active ingredient in a nutritional supplement and/or as a food, cosmetic or pharmaceutical antioxidants or colorants.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
INSTITUTO TECNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY | AVENIDA EUGENIO GARZA SADA #2501 SUR COLONIA TECNOLOGICO MONTERREY 64849 |
International Classification(s)

- [Classification Symbol]
- [Patents Count]
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Guajardo-Touche, Elsa M | San Pedro Garza Garcia, MX | 2 | 6 |
Gutierrez-Uribe, Janet A | Monterrey, MX | 2 | 6 |
Hernandez-Brenes, Carmen | San Pedro Garza Garcia, MX | 7 | 38 |
Moreno-Cuevas, Jorge E | San Pedro Garza Garcia, MX | 2 | 6 |
Serna-Saldivar, Sergio RO | Monterrey, MX | 1 | 1 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events

Matter Detail

Renewals Detail

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
PAIR load has been initiated
A preliminary load of cached data will be loaded soon. Current PAIR data will be loaded within twenty four hours.
File History PDF
Thank you for your purchase! The File Wrapper for Patent Number 20100216729 will be available within the next 24 hours.
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:

Last Refreshed On:
Changes done successfully
Important Notes on Latency of Status data
Please note there is up to 60 days of latency in this Status indicator for certain status conditions. You can obtain up-to-date Status indicator readings by ordering PAIR for the file.
An application with the status "Published" (which means it is pending) may be recently abandoned, but not yet updated to reflect its abandoned status. However, an application filed less than one year ago is unlikely to be abandoned.
A patent with the status "Granted" may be recently expired, but not yet updated to reflect its expired status. However, it is highly unlikely a patent less than 3.5 years old would be expired.
An application with the status "Abandoned" is almost always current, but there is a small chance it was recently revived and the status not yet updated.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.